Related by context. All words. (Click for frequent words.) 82 HGS ETR1 77 HGS ETR1 mapatumumab 76 alvespimycin 76 evaluating tivozanib 76 mapatumumab 76 oral prodrug 74 MAGE A3 ASCI 74 IMC A# 73 elotuzumab 73 CYT# potent vascular disrupting 73 OXi# 73 investigational humanized monoclonal antibody 73 HGS# 73 PXD# 73 refractory chronic lymphocytic 73 Panzem R NCD 73 novel VDA molecule 73 docetaxel Taxotere R 73 axitinib 73 erlotinib Tarceva ® 72 interferon gamma 1b 72 virus HCV protease inhibitor 72 adecatumumab MT# 72 lintuzumab 72 oral picoplatin 72 ganetespib 72 IMC #B 72 forodesine 72 metaglidasen 72 HCD# [002] 72 MGCD# [001] 72 fosbretabulin 72 neratinib 72 IMA# 72 oral ridaforolimus 72 Omacetaxine 72 galiximab 72 CCX# 72 MCSP respectively 72 generation Hsp# inhibitor 71 targeting CD# 71 dacetuzumab 71 orally administered inhibitor 71 Cloretazine ® 71 Randomized Phase 71 Azedra 71 FOLFOX6 chemotherapy regimen 71 INCB# [001] 71 MGd 71 Seliciclib 71 ZOLINZA 71 ENMD # 71 Sym# 71 lintuzumab SGN 71 liposomal formulation 71 CD# CEA 71 PEG SN# 71 receptor tyrosine kinase inhibitor 71 SAR# [004] 71 GRN#L 71 dasatinib Sprycel ® 71 AAG geldanamycin analog 71 Tyrima 71 CYC# 71 TO AVOID PREGNANCY WHILE 71 HuLuc# 71 agonistic human 71 Aplidin 71 Tarceva TM 71 LymphoStat B belimumab 71 pharmacodynamic markers 71 trastuzumab Herceptin R 71 5 FU leucovorin 71 bortezomib Velcade 71 K ras mutations 71 Hsp# Inhibitor 71 AEG# 71 OMP #M# 71 Aflibercept 71 cMET 71 Granulocyte Colony Stimulating Factor 70 docetaxel Taxotere ® 70 YONDELIS 70 HuMax EGFr 70 maximally tolerated dose 70 PSMA ADC 70 RGB # 70 TELCYTA 70 ZK EPO 70 Darinaparsin 70 Omacetaxine mepesuccinate 70 antibody MAb 70 Elotuzumab 70 Panzem NCD 70 Blinatumomab 70 tumor xenograft models 70 cetuximab Erbitux R 70 HER2 positive metastatic breast 70 Cannabinor 70 CR# vcMMAE 70 hematological tumors 70 CA4P 70 orally bioavailable 70 demonstrated antitumor activity 70 investigational monoclonal antibody 70 ongoing Phase 1b 70 Exherin TM 70 Imprime PGG 70 huC# DM4 70 mertansine 70 Glufosfamide 70 ELACYT 70 OncoVEX GM CSF 70 tanespimycin 70 FOLOTYN ® 70 anti EGFR antibody 70 urocortin 2 70 entinostat 70 IAP inhibitor 70 Aplidin R 70 metastatic castration resistant 70 PSN# [002] 70 Xanafide 70 antibody MT# 70 Aurora kinase 70 PNP inhibitor 70 VEGFR2 inhibitor 70 radiation sensitizer 70 R lenalidomide 70 phase IIb clinical 70 Bortezomib 70 HCV protease 70 PDX pralatrexate 70 enzastaurin 70 evaluating Xcytrin 69 phase Ib 69 vidofludimus 69 mGluR5 NAM 69 selective androgen receptor modulator 69 sorafenib tablets 69 CCR5 mAb 69 Romidepsin 69 XL# XL# 69 MyVax R 69 selective modulator 69 Allovectin 7 R 69 TOCOSOL Paclitaxel 69 riociguat 69 CORT # 69 Cloretazine R VNP#M 69 systemic anaplastic large 69 Phase Ib II 69 selective kinase inhibitor 69 candidate CRLX# 69 sunitinib Sutent ® 69 pomalidomide 69 eniluracil 69 XL# XL# XL# XL# 69 Carfilzomib 69 sunitinib malate 69 FEMALES SHOULD BE ADVISED 69 humanised monoclonal antibody 69 MEK inhibitor RDEA# 69 evaluating satraplatin 69 MEK Inhibitor 69 systemically administered 69 PRT# 69 Phase 2b Clinical Trial 69 Pivotal Phase 69 alkylating agent 69 anti leukemic 69 R#/MEM # 69 CBLC# 69 DAVANAT 69 cediranib 69 Preclinical studies suggest 69 velafermin 69 Initiate Phase 69 dasatinib Sprycel 69 valopicitabine 69 Xeloda ® 69 Vitaxin 69 imatinib Gleevec ® 69 Cloretazine 69 Golimumab 69 #ME# 69 pertuzumab 69 ISTODAX 69 Phase Ib clinical trials 69 trastuzumab DM1 T DM1 69 pathophysiological effects 69 CDK inhibitor 69 Combination REOLYSIN R 69 cilengitide 69 nucleoside analog 69 Epratuzumab 69 BRAF inhibitor 69 pan HDAC inhibitor 69 Genasense ® oblimersen 69 dependent kinase inhibitor 69 sorafenib Nexavar ® 69 Bezielle 68 Voreloxin 68 Vidaza ® 68 HuMax CD# 68 TOCOSOL Camptothecin 68 Exelixis compounds 68 nab paclitaxel 68 compound INCB# 68 APOPTONE 68 AEGR 68 Annamycin 68 Epothilones 68 ONCONASE R 68 Onyx Pharmaceuticals Announces 68 Deforolimus 68 Perifosine 68 OMP #R# 68 Phase #b/#a clinical 68 EGFR HER2 68 PKC# 68 Epothilone D 68 motesanib 68 sorafenib Nexavar 68 panitumumab Vectibix 68 Sapacitabine 68 recurrent glioblastoma multiforme 68 alfa 2a 68 telomerase inhibitor drug 68 tezampanel NGX# 68 Phase 1a clinical 68 MKC# MT 68 R sorafenib tablets 68 alpha folate receptor 68 PLK1 SNALP 68 BRIM3 68 pan histone deacetylase 68 docetaxel chemotherapy 68 CTAP# Capsules 68 human IgG1 monoclonal 68 non nucleoside inhibitor 68 Phase #/#a trial 68 SUCCEED trial 68 estramustine 68 Traficet EN 68 monoclonal antibody IgG1 Mab 68 oral deforolimus 68 5 fluorouracil leucovorin 68 voreloxin 68 relapsed MM 68 Antitumor Activity 68 unique alkylating agent 68 zanolimumab 68 lenalidomide Revlimid R 68 oral JAK1 68 rhIGFBP 3 68 Akt inhibitor 68 Phase IIb III 68 ACTEMRA TM 68 IgG1 monoclonal antibody 68 DXL# 68 vinca alkaloid 68 sorafenib Nexavar R 68 AQ4N 68 highly selective inhibitor 68 pharmacodynamic PD 68 TRIOLEX HE# APOPTONE HE# 68 Ocrelizumab 68 Randomized Phase II 68 CoFactor 68 LEP ETU 68 novel tubulin binding 68 protein kinase inhibitor 68 SPRYCEL ® 68 mitogen activated ERK kinase 68 xenograft models 68 Panzem R 68 KRN# 68 PI3K/Akt pathway inhibitor 68 Completes Patient Enrollment 68 CDK cyclin dependent 68 gemcitabine cisplatin 68 LymphoStat B TM 68 teriflunomide 68 Telik logo TELINTRA 68 Meets Primary Endpoint 68 HSP# inhibitor 68 2 methoxyestradiol 68 cetuximab Erbitux ® 68 drug conjugate 68 PDE4 inhibitor 68 Archexin 68 vosaroxin 68 Telintra 68 relapsed refractory multiple myeloma 68 velafermin belinostat 68 BRIM2 68 BAY #-# 68 Ceflatonin 68 CB2 selective receptor agonist 68 ON #.Na 68 bevacizumab Avastin R 68 Xelox 68 CYP#A# CYP#D# 67 antiangiogenic activity 67 TLK# 67 nilotinib Tasigna ® 67 low dose cytarabine 67 XL# inhibits 67 #D#C# 67 XL# anticancer compounds 67 deforolimus 67 recurrent metastatic ovarian cancer 67 AP# [003] 67 huN# DM1 67 ® bortezomib 67 Insegia 67 Apoptone 67 IL# PE#QQR 67 Triapine R 67 TRAIL receptor antibodies 67 Kahalalide F 67 histone deacetylase inhibitor 67 NXL# 67 Immunotherapeutic 67 multicenter Phase II 67 ascending dose 67 celgosivir 67 systemic RNAi therapeutic 67 NEUVENGE 67 Presents Preclinical 67 FUSILEV enhances 67 Phase Ib study 67 Trastuzumab DM1 67 receptor inhibitor 67 Phase Ib clinical 67 EndoTAG TM -1 67 TOLAMBA 67 EOquin TM 67 ASONEP 67 pharmacokinetic PK study 67 Talabostat 67 CCR9 antagonist 67 Methylnaltrexone 67 favorable pharmacokinetic profile 67 Virulizin ® 67 polymerase inhibitor 67 Ophena TM 67 Initiates Phase II 67 GVAX ® 67 XmAb# 67 Chemophase 67 cetuximab Erbitux 67 alpha#beta# integrin 67 PEGPH# 67 Presents Preclinical Data 67 Azacitidine 67 pharmacodynamic effects 67 MET amplification 67 TransVax ™ 67 Personalized Immunotherapy 67 Maribavir 67 Factor Receptor 67 adecatumumab 67 elacytarabine 67 safety tolerability pharmacokinetic 67 romidepsin 67 Symadex 67 Pivotal Phase III 67 ZYBRESTAT fosbretabulin 67 GAP #B# 67 depsipeptide 67 CLORETAZINE TM VNP#M 67 lumiliximab 67 IFN α 67 carboplatin paclitaxel 67 Rigel R# 67 Anti Tumor 67 plus prednisone prednisolone 67 pralatrexate 67 potent antiproliferative 67 TELINTRA 67 Gleevec resistant 67 Amrubicin 67 preclinical efficacy 67 lapatinib Tykerb 67 Zalypsis 67 sodium glucose cotransporter 67 Aurora Kinase 67 VNP#M 67 R roscovitine 67 midstage clinical 67 MEK inhibitor 67 protein tyrosine phosphatase 1B 67 RAV# 67 PROSTVAC VF 67 Vidaza azacitidine 67 Quinamed 67 antitumor activity 67 Kinase Inhibitor 67 Genasense oblimersen sodium Injection 67 Xcytrin R 67 castrate resistant prostate cancer 67 topoisomerase II inhibitor 67 nonclinical studies 67 Alocrest 67 PROVENGE sipuleucel T 67 Trofex 67 bevacizumab Avastin ® 67 HuMax CD4 67 gemcitabine Gemzar 67 ALN TTR 67 JAK inhibitor 67 taxane resistant 67 Entereg R 67 milatuzumab 67 Phase 1b 67 thymalfasin 67 TREANDA 67 dextromethorphan quinidine 67 Tasimelteon 67 cell lymphoma CTCL 67 apoptosis proteins 67 Pralatrexate 67 viral kinetics 67 Dasatinib 67 selective orally bioavailable 67 otelixizumab 67 AKT inhibitor 67 refractory acute myeloid 67 CD# monoclonal antibody 67 sapacitabine 67 leukemia AML 67 humanized anti 67 Trial Evaluating 67 Romiplostim 66 investigational protease inhibitor 66 tolerability pharmacokinetics 66 Serdaxin ® 66 G#DT 66 IAP inhibitors 66 PEGylated Fab fragment 66 subcutaneous formulation 66 XL# XL# XL# 66 lesinurad 66 plus dacarbazine 66 talactoferrin 66 Pertuzumab 66 vascular disrupting agent 66 paclitaxel Taxol ® 66 FOLFOX6 66 cytokine refractory 66 XYOTAX TM 66 EGFR TKI 66 ALN PCS 66 Azedra TM 66 small molecule tyrosine 66 Aurexis 66 tezampanel 66 PEG Interferon lambda 66 tubulin inhibitor 66 belinostat 66 Valortim ® 66 myelofibrosis polycythemia vera 66 Proxinium TM 66 nucleotide analog 66 trabectedin 66 busulfan 66 paclitaxel cisplatin 66 phase IIb III 66 gefitinib Iressa 66 avosentan 66 TransVax tm 66 Bicifadine 66 GMX# 66 peptibody 66 ALN TTR# 66 ADP receptor antagonist 66 MetMAb 66 luteinizing hormone releasing 66 generation purine nucleoside 66 vascular disrupting agents 66 selective antagonist 66 anti amnesic 66 histone deacetylase HDAC inhibitor 66 AeroLEF TM 66 custirsen 66 peptidic compound 66 TransVax TM 66 Zemplar Capsules 66 gemcitabine Gemzar ® 66 Novolimus 66 TBC# 66 XOMA 3AB 66 radezolid 66 Solazed TM 66 sunitinib Sutent 66 telomerase therapeutic 66 solid tumors ZYBRESTAT 66 alefacept 66 imatinib resistant 66 Initiates Phase III 66 tyrosine kinase inhibitor 66 q8h 66 sapacitabine CYC# 66 REOLYSIN ® 66 cannabinor 66 R roscovitine CDK cyclin 66 registrational trial 66 Achieves Primary Endpoint 66 IL #E 66 ocular formulation 66 peripherally acting 66 obatoclax 66 ThermoDox ® clinical 66 phase IIb trial 66 MEND CABG II 66 Oral Fingolimod 66 BiovaxID TM 66 OvaRex R 66 Initiated Phase 66 sarcoma melanoma 66 bortezomib Velcade R 66 D aspartate NMDA receptor 66 ruxolitinib 66 BiTE ® 66 HCV NS5B polymerase 66 rALLy clinical trial 66 EFAPROXYN 66 certain protein tyrosine 66 sitaxsentan 66 refractory multiple myeloma 66 Tarvacin TM 66 visilizumab 66 CEQ# 66 rindopepimut 66 proteasome inhibitor 66 Aclidinium 66 pro apoptotic 66 Thiovir 66 Pazopanib 66 metastatic RCC 66 phase IIa clinical 66 crizotinib PF # 66 TRAIL R2 66 seliciclib 66 amrubicin 66 trastuzumab emtansine T DM1 66 SCH # 66 pharmacokinetic PK 66 JAK2 inhibitor 66 CD# antibody [001] 66 aflibercept VEGF Trap 66 EGFr 66 Sudhir Agrawal D.Phil 66 pharmacodynamic properties 66 Curaxin CBLC# 66 PEGylated anti 66 glufosfamide 66 ixabepilone 66 AVOREN 66 5 HT6 receptor 66 Stedivaze 66 humanized interleukin 6 66 HCV SPRINT 66 ALN VSP 66 MYDICAR ® 66 mGluR5 negative 66 JAK inhibitors 66 omega interferon 66 Poly ICLC 66 bosutinib 66 Xcellerated T Cells 66 GRNVAC1 66 castration resistant prostate cancer 66 Solorel TM 66 IMiDs R 66 replicon 66 metastatic HRPC 66 lymphoid malignancies 66 JVRS 66 Vaxfectin TM 66 trastuzumab DM1 66 Vidaza R 66 chemopreventive agent 66 Phase III Pivotal 66 TRX1 66 IMiDs ® 66 MT#/MEDI-# 66 AVASTIN 66 Lenocta 66 MEK inhibitors 66 Enzastaurin 66 Epidermal Growth Factor Receptor 66 Ambrisentan 66 Gemzar ® 66 weekly subcutaneous injections 66 isoform selective 66 TLR9 agonist 66 PANVAC VF 66 PROVENGE ® 66 telaprevir VX 66 treatment naive genotype 66 immunomodulatory 66 panobinostat 66 Prostate AdenoCarcinoma Treatment 66 non nucleoside HCV 66 pharmacodynamic profile 66 Randomized Double blind 66 Elagolix 66 fluoropyrimidine 66 Phase IIIb clinical 66 factor HGF 66 MOZOBIL 66 Phase 1b clinical trials 66 CYT# 66 immunomodulating 66 liposomal doxorubicin 66 interleukin IL -# 66 Vandetanib 66 Amigal 66 CIMZIA TM 66 SIRT1 activators 66 Iloperidone 66 novel histone deacetylase 66 APPRAISE 66 Valortim R 66 dose escalation clinical 66 HCV RNA polymerase 66 tumors GIST 66 Pharmacokinetics PK 66 TNF alpha selectively neutralizing 66 relapsed multiple myeloma 66 T#I [002] 66 antitumor effect 66 NOX E# 66 Onconase 66 torezolid phosphate 66 GRN# 66 Bafetinib 66 Tezampanel 66 refractory AML 66 vorinostat 66 Initiates Enrollment 66 PRTX 66 anticancer activity 66 androgen independent 66 Reports Preclinical Data 66 Hormone Refractory Prostate Cancer 66 ponatinib 66 BiTE antibody 66 XP# XP# 66 CD4 monoclonal antibody 66 idarubicin 66 PI3K/mTOR 66 novel emulsion formulation 65 small molecule Hedgehog 65 Peginterferon alfa 2b 65 AVE# 65 BZL# 65 AMD# [003] 65 TACI Ig 65 Allovectin 7 ® 65 irinotecan containing 65 rNAPc2 65 GAMMAGARD 65 cisplatin resistant 65 EZN 65 Refractory Hodgkin Lymphoma 65 Ixempra 65 pharmacokinetic interactions 65 Taxotere chemotherapy 65 ARIKACE ™ 65 Forodesine HCl 65 Metastatic Melanoma 65 HDAC Inhibitor 65 HER2 expression 65 cisplatin gemcitabine 65 delta isoform 65 NS5B polymerase 65 DermaVir Patch 65 including eniluracil ADH 65 candidate deforolimus 65 thalidomide Thalomid 65 5alpha reductase 65 refractory CTCL 65 sipuleucel T 65 CYP#A# substrate 65 ALN HPN 65 SAR# [002] 65 Nanobody 65 TTF Therapy 65 triggers apoptosis programmed 65 Vicinium TM 65 Obatoclax 65 Plicera 65 DPP4 65 r hGH 65 advanced metastatic renal 65 ARRY # 65 multi kinase inhibitor 65 standard chemotherapy regimen 65 IMiDs 65 Cloretazine R 65 targeted radiotherapeutic 65 Trastuzumab 65 novel peptide 65 palifosfamide Zymafos TM 65 decitabine 65 EndoTAG 65 hA# 65 JAK1 65 TLR7 agonist 65 phase IIb study 65 Azedra ™ 65 Aptivus ® 65 Talactoferrin 65 trial evaluating PRX# 65 polysaccharide polymer 65 PHX# 65 immunomodulator 65 refractory gout 65 RG# [001] 65 brentuximab vedotin SGN 65 Zoraxel TM 65 unresectable tumors 65 Capesaris 65 Zolinza 65 ancrod 65 antiangiogenic agents 65 Nexavar sorafenib 65 evaluating picoplatin 65 soluble tumor necrosis 65 plus prednisone 65 pegylated liposomal doxorubicin 65 signal detection CTSD 65 epigenetic therapies 65 Albuferon TM 65 cytostatic 65 class mGluR5 inhibitor 65 cytoprotective 65 generation antisense inhibitor 65 EndoTAGTM 1 65 assessing T DM1 65 compound AEZS 65 MAXY alpha 65 Neulasta ® 65 varespladib 65 potent antitumor activity 65 XL# SAR# 65 ® lenalidomide 65 octreotide acetate 65 DOS# 65 Phase 2a trial 65 KSP inhibitor 65 related apoptosis inducing 65 Tarvacin Anti Cancer 65 mda 7 65 Copegus ribavirin 65 dose escalation Phase 65 Hsp# inhibition 65 trastuzumab Herceptin ® 65 investigational hepatitis C 65 Phase #b/#a 65 selective inverse agonist 65 mRCC 65 Trofex TM 65 flavopiridol 65 initiate Phase 1b 65 rALLy 65 Vidofludimus 65 PD LID 65 TRO# 65 evaluating Actimmune 65 antiangiogenic 65 oncolytic 65 gemcitabine carboplatin 65 treatment naïve genotype 65 tiuxetan 65 CINTREDEKIN BESUDOTOX 65 p# inhibitor 65 Neuvenge 65 regorafenib 65 Liposomal 65 leukemia CLL 65 Temsirolimus 65 cleavable linker 65 Panitumumab 65 ospemifene 65 IMPDH inhibitor 65 TLR9 65 TORISEL 65 pharmacokinetics pharmacodynamics 65 interferon beta 1a infertility 65 synthetic retinoid 65 iniparib 65 arsenic trioxide injection 65 CD# expressing 65 Medullary Thyroid Cancer 65 dacetuzumab SGN 65 Luteinizing Hormone Releasing Hormone 65 Zenvia ™ 65 aplindore 65 ATL# [001] 65 R Saizen R 65 Tanespimycin 65 anti CTLA 65 Known hypersensitivity 65 hemagglutination inhibition HAI 65 EOquin 65 Initiates Phase 65 Phase #b/#a trial 65 brostallicin 65 Pharmacodynamic 65 Tesetaxel 65 antiangiogenic therapy 65 Begins Dosing 65 CIMZIA TM certolizumab pegol 65 potentially hepatotoxic 65 GLP toxicology studies 65 GVAX R 65 oblimersen 65 immune modulating 65 Zybrestat 65 irinotecan doxorubicin oxaliplatin paclitaxel 65 Genz # 65 ritonavir boosted 65 GLPG# 65 randomized Phase 2b 65 dose cohort 65 sodium thiosulfate STS 65 mitoxantrone plus 65 pharmacodynamic parameters 65 ATC ovarian cancer 65 PDE# 65 Vaxfectin ® 65 partial agonist 65 delafloxacin 65 interferon alfa 2b 65 saline placebo 65 kidney urologic 65 Pegylated 65 hormone LHRH antagonist 65 FGFR 65 Marqibo TM 65 L BLP# 65 atacicept 65 Pemetrexed 65 oral nucleoside analogue 65 adalimumab Humira 65 oxidative stress inducer 65 kinase inhibition 65 5 Fluorouracil 65 NS#/#A protease 65 lymphoma CTCL 65 tramiprosate Alzhemed TM 65 NEUGENE antisense 65 Vicriviroc 65 Androxal TM 65 MDV# 65 Oral NKTR 65 multicenter Phase III 65 ApoB SNALP 65 Vascular Disrupting Agent 65 gemtuzumab ozogamicin 65 secretory phospholipase A2 sPLA2 65 Phase 1b trial 65 stated Michelle Berrey 65 farletuzumab 65 BiTE R 65 Aganocide 65 CG# [003] 65 Azixa 65 5 HT2A serotonin 65 KIACTA ™ 65 clinical trials Archexin ® 65 antiproliferative effects 65 TMC# [002] 65 volociximab 65 MT# MEDI 65 CTA# Injection 65 Triolex 65 dacarbazine 65 antitumor effects 65 class anticancer quinolone 65 erlotinib Tarceva 65 non nucleoside 65 metastatic colorectal 65 lenalidomide dexamethasone 65 microtubule inhibitor 65 Aurora kinase inhibitor 65 Oral Calcitonin 65 imatinib therapy 65 anionic backbone 65 ALK inhibitor 65 TRAIL Receptor 65 Reolysin 65 talabostat 65 GSK # 65 humanized monoclonal antibody 65 PEG PAL 65 INGN 65 pharmacogenomic translational research 65 Y2 receptor 65 EOquin TM phase 65 THR beta agonist 65 acetonide FA 65 posaconazole 64 IRX 2 64 PROSTASCINT R 64 recombinant PSMA vaccine 64 phosphate S1P 64 Novel Oral 64 Palifosfamide 64 HQK 64 potent suppressor 64 Pimavanserin 64 LY# [003] 64 Alfacell proprietary ribonuclease 64 primary hypercholesterolemia 64 metastatic castrate resistant 64 preclinically 64 Initiates Clinical 64 IMiDs ® compound 64 anthracycline taxane 64 refractory cutaneous T 64 RIGScan CR 64 Tumour Vascular Disrupting Agent 64 MAGE A3 64 Factor VIIa 64 specific lectin receptors 64 Antiviral Activity 64 Cethromycin 64 prostate cancer CRPC 64 ISIS # 64 OvaRex ® MAb 64 SinuNase TM 64 TKM ApoB 64 Bayer HealthCare Onyx Pharmaceuticals 64 oxaliplatin Eloxatin 64 Abiraterone acetate 64 antisense inhibitors 64 Brentuximab Vedotin SGN 64 vandetanib 64 Dose Escalation 64 T#I mutant 64 LymphoStat B 64 refractory CLL 64 administered subcutaneously 64 eritoran 64 Phase 2b Trial 64 fallopian tube cancers 64 davunetide intranasal AL 64 pharmacodynamic profiles 64 hematological cancers 64 R# #mg BID 64 NEUGENE 64 Irinotecan 64 Tamibarotene 64 immune modulator 64 pegylated interferons 64 CRLX# 64 SB# ONX 64 metastatic renal cell carcinoma 64 Clolar ® 64 indibulin 64 cutaneous T cell 64 imatinib Gleevec 64 angiogenesis inhibitor 64 Zorbtive TM 64 JAK#/JAK# 64 immunostimulatory 64 CA9 SCAN 64 signal transduction inhibitor 64 initiated Phase 1b 64 KNS # 64 SUTENT ® 64 EGFr expressing metastatic colorectal 64 mTOR inhibition 64 ATRA IV 64 Allovectin 7 64 ZADAXIN ® 64 Diffuse Large B 64 EGFR inhibitors 64 novel synthetic PEGylated 64 Kinoid 64 pralatrexate injection folate analogue 64 Ad5FGF 4 64 receptor inhibiting monoclonal 64 effector function 64 antiangiogenic agent 64 VEGF inhibitors 64 standard chemotherapy regimens 64 novel DACH platinum 64 goserelin 64 Multimeric 64 Cetrorelix 64 triphendiol 64 apremilast